ACADIA Pharmaceuticals is a biopharmaceutical company with its focus on innovative treatments addressing unmet medical needs in neurological and related central nervous system disorders. Pimavanserin, which is in Phase III clinical development as a potential first-in-class treatment for Parkinson’s disease psychosis, leads the company’s pipeline of product candidates. All the company’s product candidates are small molecules emanating from discoveries made at ACADIA. For more information, visit the company’s Web site at www.acadia-pharm.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: